Cytokine Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Cytokine Market Size

Global Cytokine Market reached US$ 72.3 billion in 2022 and is expected to reach US$ 132.2 billion by 2030, growing with a CAGR of 7.6 % during the forecast period 2023-2030.

Small proteins known cytokines provide a key role in regulating the development and activity of blood and immune system cells. They signal the immune system to function once they are released. All blood cells and other cells that support the body's immunological and inflammatory responses are affected by cytokines. By transmitting signals that can cause abnormal cells to die and normal cells to live longer, they also support anti-cancer activities.

Therapies that target cytokines have attracted an excessive amount of attention. Drugs that modify cytokine activity are being developed by researchers and pharmaceutical companies to treat a variety of diseases, including autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease. In order to regenerate and repair tissue, cytokines are essential. In many situations, such as wound healing and muscle regeneration, researchers are looking into how cytokines might be used to aid healing and tissue regeneration.

Market Scope

For more details on this report Request for Sample

Market Dynamics

The Advancement of New Technologies

Cancer immunotherapy may continue to be greatly influenced by cytokines, which have shown to be effective in the treatment of cancer. Cloned cytokines have been utilised to treat a variety of cancers, hepatitis C, and hepatitis B. Additionally efficient at treating a rare hereditary condition, cytokines. Additionally, cytokines can aid in preventing the growth of cancer when they are generated in response to inflammation, infection, and immunity. The highest market share is expected to be attributed to the therapeutic use of cytokines in the treatment of cancer.

For instance, according to an article published in National Cancer Institute 2022, stated that, a recent study in mice reveals that scientists have created small "drug factories" that can be put close to abdominal tumours to treat cancer. In rodent models of ovarian and colorectal cancer, the drug factories eradicated tumours by producing the immune-stimulating cytokine interleukin-2 (IL-2).

Beginning in 2022, clinical trials of this strategy on ovarian cancer patients are expected. An instance of a cytokine is IL-2, which "is a known potent activator of T cells—the fighter cells of the immune system—and boosts their normal ability to eradicate cancer cells." Therefore, the rise of innovations aids in accelerating market expansion.

The Rise in Clinical Trails

There are a number of factors contributing to the increase in cytokine-related clinical trials and investments, which represent both scientific developments and the possibility of major medicinal advancements. The development of more focused and efficient cytokine-based therapeutics has been made possible by developments in biotechnology and pharmaceutical research. With the use of recombinant DNA technology, cytokines can be produced with more selectivity and fewer negative effects. Investors and pharmaceutical corporations are interested in developing novel medicines and making substantial medical improvements. Research and clinical trial funding may grow if innovative cytokine-based medications are developed.

For instance, in May 2023, The U.S. Food and Drug Administration (FDA) approved CytoAgents, Inc., a clinical-stage biotechnology company working on a safe, effective treatment for Cytokine Release Syndrome (CRS), permission to move on with the study. This approval permits the beginning of a U.S. Phase 1b/2a clinical trial for the drug CTO1681 to treat CRS in lymphoma patients receiving CAR T-Cell Therapy under its Investigational New Drug (IND) application. As the majority of patients receiving CAR T therapy for their malignancy have CRS and related neurotoxicity, there is a significant unmet medical need in this field.

Moreover, in January 2023, Using both new and existing investors, Synthekine Inc., a provider of tailored cytokine therapies, announced the successful conclusion of a $100 million Series C fundraising headed by The Column Group. The company's IL-12 partial agonist programme, which is now in IND-enabling studies, will also be advanced with the help of the funds. Although IL-12 is a potent cytokine with the potential to treat cancer, its administration has been constrained by a restricted therapeutic window and potential life-threatening side effects in patients. Thus above factors helps to accelerate the market growth.

Cytokines Have a Short Half-Life in the Body

Due to their physiological functions, regulation, and the immune system's requirement for dynamic control over immunological responses, cytokines have a short half-life in the body.  For instance, signalling molecules called cytokines coordinate immune responses. Controlling these reactions quickly and precisely is necessary for the immune system. Cytokines' fast production, release, and degradation due to their short half-lives enable the immune system to adjust its responses to changing circumstances.

These biologic medicines' limited effectiveness is considerably hampered by their brief half-lives. These drugs may be administered less frequently and at lower doses if the stability of these proteins were to increase. As a result, researchers have created a number of techniques to increase the half-life of cytokines in vivo and target them more specifically to particular tissues and organs. Thus, the market's expansion will be hindered by the drug's short half-life in the body.

For more details of the report, Request for sample

Segment Analysis

The global cytokine market is segmented based on type, application, end users and region.

Cytokines Play a Critical Part in the Treatment of Cancer

With their capacity to regulate the immune response and have an impact on the tumour microenvironment, cytokines play a critical part in the treatment of cancer. It has been investigated to use cytokine-based therapeutics to take advantage of the immune system's capacity to identify and target cancer cells. The presentation of tumour antigens to immune cells can be aided by cytokines. As a result, the immune system is better able to identify cancer cells as foreign and respond to them effectively. 

The tumour microenvironment, which consists of elements like blood vessels, stromal cells, and immune cells, can be influenced by cytokines. Cytokines can modify the tumour microenvironment to produce circumstances that are less conducive to tumour development and survival. Factors such as the increased prevalence of cancer, clinical research, and funding in the field of cancer therapy fuel segment growth. 

For instance, according to National Cancer Institute, stated that, in the US, 2.0 million people will be given a cancer diagnosis in 2023. Breast cancer will be the most prevalent cancer diagnosis in 2018, affecting an estimated 297,790 women and 2,800 males. With 288,300 predicted cases, prostate cancer is the most prevalent cancer diagnosis among males and the second most frequent overall. The cancer segment is therefore expected to drive the segment growth over the projected period as a result of the causes mentioned above.

Geographical Share

Rising Product Approvals and Product Launches in the North American Region

North America is expected to dominate the cytokine market, due to the rising prevalence of cancer, product launches, FDA approvals of products, and research and development initiatives in the region.

For instance, on June 6, 2022, Amgen announced that the U.S. Food and Drug Administration (FDA) approved RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. 

Moreover, in January 2023, in order to include Canadian sites in the pivotal Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) randomised, controlled trial, CytoSorbents Corporation, a pioneer in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, has received regulatory approval from Health Canada. Therefore, as a result of all of the above, it is expected that North America would account for the largest market share throughout the projection period.

COVID-19 Impact Analysis

Cytokines are small proteins that play a crucial role in the immune response to infections, including COVID-19. An excessive release of cytokines, known as a cytokine storm, can have negative consequences. In COVID-19 patients, an increase in cytokine production is associated with severe symptoms, including acute lung injuries, blood clots, and fever. The severity of COVID-19 disease is linked to the virus-induced cytopathic effects and escape, which lead to the release of pro-inflammatory cytokines. 

Mortality in COVID-19 patients has been linked to the presence of the so-called cytokine storm induced by the virus. Therefore, controlling cytokine storm is vital in COVID-19. Recent studies have shown that the level of inflammatory cytokines is increased in COVID-19, and several cytokines play a crucial role in the pathogenesis of COVID-19. Understanding the differences in cytokine expression is considered critical for the conquest of COVID-19.

By Type

• Chemokines
• Interferons
• Interleukins
• Tumor necrosis factor (TNF)
• Monokines
• Lymphokines
• Colony-stimulating factors (CSF)

By Application

• Cancer
• Orthopedic
• Dermatology
• Others

By End Users

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Research Institutes
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On March 27, 2023, The U.S. Food and Drug Administration (FDA) has approved CLN-617, a fusion protein composed of two potent and synergistic antitumor cytokines, IL-2 and IL-12, with a collagen binding domain intended for retention in the tumour microenvironment (TME) after intratumoral injection, according to Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology therapies. In a Phase 1 trial, Cullinan Oncology will initially assess CLN-617 in patients with advanced solid tumours.
• On June 15, 2023, Genentech, a member of the Roche Group, announced that the FDA had approved Columvi (glofitamab-gxbm) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) that is not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, following two or more lines of systemic therapy.
• On May 19, 2023, The FDA has approved EPKINLYTM (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL resulting from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), following two or more lines of systemic therapies.
• In May 2021, Ankyra Therapeutics and Lonza have signed an agreement to create a fusion protein for cytokines. In order to advance their first complex chemical targeting intratumoral injection in solid tumours into clinical development, Ankyra will draw on Lonza's experience with next-generation modalities. In order to meet a crucial deadline for an IND submission, Lonza will deliver a programme intended to shorten time to clinic.

Competitive Landscape

The major global players in the market include CytoAgents, Cullinan Oncology, Inc, Genentech, Inc, AbbVie Inc, Sanofi, Novartis AG, Pfizer Inc, F. Hoffmann-La Roche Ltd , Merck KGaA, GenScript and among others.

Why Purchase the Report?

• To visualize the global cytokine market segmentation based on type, application, end users and region,as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of cytokine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Cytokine market report would provide approximately 61tables, 58figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies